|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CMPK1 |
Gene summary for CMPK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CMPK1 | Gene ID | 51727 |
| Gene name | cytidine/uridine monophosphate kinase 1 | |
| Gene Alias | CK | |
| Cytomap | 1p33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P30085 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51727 | CMPK1 | GSM4909286 | Human | Breast | IDC | 2.83e-05 | -1.08e-01 | 0.1081 |
| 51727 | CMPK1 | GSM4909291 | Human | Breast | IDC | 1.33e-03 | -3.91e-01 | 0.1753 |
| 51727 | CMPK1 | GSM4909293 | Human | Breast | IDC | 7.03e-06 | -2.92e-01 | 0.1581 |
| 51727 | CMPK1 | GSM4909296 | Human | Breast | IDC | 9.75e-29 | -5.89e-01 | 0.1524 |
| 51727 | CMPK1 | GSM4909297 | Human | Breast | IDC | 3.18e-20 | -4.63e-01 | 0.1517 |
| 51727 | CMPK1 | GSM4909301 | Human | Breast | IDC | 1.01e-09 | -4.12e-01 | 0.1577 |
| 51727 | CMPK1 | GSM4909302 | Human | Breast | IDC | 3.48e-10 | -4.18e-01 | 0.1545 |
| 51727 | CMPK1 | GSM4909304 | Human | Breast | IDC | 4.46e-06 | -3.46e-01 | 0.1636 |
| 51727 | CMPK1 | GSM4909306 | Human | Breast | IDC | 3.84e-10 | -3.91e-01 | 0.1564 |
| 51727 | CMPK1 | GSM4909307 | Human | Breast | IDC | 8.41e-13 | -4.44e-01 | 0.1569 |
| 51727 | CMPK1 | GSM4909308 | Human | Breast | IDC | 4.17e-07 | -3.99e-01 | 0.158 |
| 51727 | CMPK1 | GSM4909309 | Human | Breast | IDC | 2.63e-17 | -5.27e-01 | 0.0483 |
| 51727 | CMPK1 | GSM4909311 | Human | Breast | IDC | 3.46e-38 | -5.25e-01 | 0.1534 |
| 51727 | CMPK1 | GSM4909312 | Human | Breast | IDC | 5.86e-16 | -3.49e-01 | 0.1552 |
| 51727 | CMPK1 | GSM4909313 | Human | Breast | IDC | 4.17e-04 | -2.78e-01 | 0.0391 |
| 51727 | CMPK1 | GSM4909317 | Human | Breast | IDC | 1.14e-04 | -3.73e-01 | 0.1355 |
| 51727 | CMPK1 | GSM4909319 | Human | Breast | IDC | 1.25e-44 | -6.02e-01 | 0.1563 |
| 51727 | CMPK1 | GSM4909320 | Human | Breast | IDC | 1.53e-11 | -6.34e-01 | 0.1575 |
| 51727 | CMPK1 | GSM4909321 | Human | Breast | IDC | 5.27e-25 | -5.12e-01 | 0.1559 |
| 51727 | CMPK1 | brca10 | Human | Breast | Precancer | 3.63e-10 | -4.68e-01 | -0.0029 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091427 | Breast | Precancer | nucleoside triphosphate biosynthetic process | 23/1080 | 85/18723 | 2.82e-10 | 2.69e-08 | 23 |
| GO:00091418 | Breast | Precancer | nucleoside triphosphate metabolic process | 26/1080 | 112/18723 | 7.72e-10 | 6.66e-08 | 26 |
| GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
| GO:00463907 | Breast | Precancer | ribose phosphate biosynthetic process | 30/1080 | 190/18723 | 4.75e-07 | 2.11e-05 | 30 |
| GO:00092607 | Breast | Precancer | ribonucleotide biosynthetic process | 29/1080 | 182/18723 | 6.05e-07 | 2.55e-05 | 29 |
| GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
| GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
| GO:00469398 | Breast | Precancer | nucleotide phosphorylation | 20/1080 | 101/18723 | 1.07e-06 | 4.18e-05 | 20 |
| GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
| GO:00091858 | Breast | Precancer | ribonucleoside diphosphate metabolic process | 20/1080 | 106/18723 | 2.37e-06 | 8.17e-05 | 20 |
| GO:00061658 | Breast | Precancer | nucleoside diphosphate phosphorylation | 19/1080 | 99/18723 | 3.23e-06 | 1.05e-04 | 19 |
| GO:00091328 | Breast | Precancer | nucleoside diphosphate metabolic process | 21/1080 | 124/18723 | 7.98e-06 | 2.17e-04 | 21 |
| GO:00091655 | Breast | Precancer | nucleotide biosynthetic process | 32/1080 | 254/18723 | 2.72e-05 | 6.21e-04 | 32 |
| GO:19012935 | Breast | Precancer | nucleoside phosphate biosynthetic process | 32/1080 | 256/18723 | 3.18e-05 | 6.97e-04 | 32 |
| GO:000914214 | Breast | IDC | nucleoside triphosphate biosynthetic process | 26/1434 | 85/18723 | 4.72e-10 | 5.06e-08 | 26 |
| GO:000914114 | Breast | IDC | nucleoside triphosphate metabolic process | 29/1434 | 112/18723 | 3.68e-09 | 3.03e-07 | 29 |
| GO:004639013 | Breast | IDC | ribose phosphate biosynthetic process | 36/1434 | 190/18723 | 3.40e-07 | 1.73e-05 | 36 |
| GO:000926013 | Breast | IDC | ribonucleotide biosynthetic process | 35/1434 | 182/18723 | 3.40e-07 | 1.73e-05 | 35 |
| GO:001969314 | Breast | IDC | ribose phosphate metabolic process | 58/1434 | 396/18723 | 1.31e-06 | 5.73e-05 | 58 |
| GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa01240 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa00983 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
| hsa012401 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa009831 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
| hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
| hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CMPK1 | SNV | Missense_Mutation | novel | c.440N>T | p.Ser147Phe | p.S147F | P30085 | protein_coding | deleterious(0.02) | benign(0.429) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| CMPK1 | SNV | Missense_Mutation | rs374502290 | c.445N>A | p.Val149Ile | p.V149I | P30085 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CMPK1 | SNV | Missense_Mutation | c.363C>A | p.Phe121Leu | p.F121L | P30085 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CMPK1 | SNV | Missense_Mutation | novel | c.504N>T | p.Lys168Asn | p.K168N | P30085 | protein_coding | tolerated(0.05) | benign(0.354) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CMPK1 | SNV | Missense_Mutation | novel | c.225N>T | p.Lys75Asn | p.K75N | P30085 | protein_coding | tolerated(0.57) | benign(0.018) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CMPK1 | SNV | Missense_Mutation | novel | c.504N>T | p.Lys168Asn | p.K168N | P30085 | protein_coding | tolerated(0.05) | benign(0.354) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CMPK1 | SNV | Missense_Mutation | rs374502290 | c.445G>A | p.Val149Ile | p.V149I | P30085 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CMPK1 | SNV | Missense_Mutation | novel | c.337N>A | p.Ala113Thr | p.A113T | P30085 | protein_coding | tolerated(0.31) | benign(0.017) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CMPK1 | SNV | Missense_Mutation | rs374502290 | c.445G>A | p.Val149Ile | p.V149I | P30085 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| CMPK1 | SNV | Missense_Mutation | c.363N>A | p.Phe121Leu | p.F121L | P30085 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51727 | CMPK1 | KINASE, ENZYME | lamivudine | LAMIVUDINE | ||
| 51727 | CMPK1 | KINASE, ENZYME | cisplatin | CISPLATIN | 21642870 | |
| 51727 | CMPK1 | KINASE, ENZYME | gemcitabine | GEMCITABINE | 21642870,22838949,22838950,24361227 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |